Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DHR stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
DHR vs A
ILLUMINA, INC.
DHR vs ILMN
JOHNSON & JOHNSON
DHR vs JNJ
ABBOTT LABORATORIES
DHR vs ABT
LOEWS CORP
DHR vs L
BERKSHIRE HATHAWAY INC
DHR vs BRK-B
REGENERON PHARMACEUTICALS, INC.
DHR vs REGN
BIOGEN INC.
DHR vs BIIB
VERTEX PHARMACEUTICALS INC / MA
DHR vs VRTX
Gilead Sciences, Inc.
DHR vs GILD
Moderna, Inc.
DHR vs MRNA
Eli Lilly and Company
DHR vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DHR can reaccelerate growth and expand margins meaningfully above the current 2.9% revenue growth and 19.1% operating margin, then you can justify holding or adding; otherwise, the relative valuation argues for caution because DHR trades at 39.1x earnings versus AMGN’s 26.6x with implied downside to $134.45.
DHR trades at a 39.1x P/E versus AMGN at 26.6x, yet DHR’s growth and profitability are materially weaker. The model’s implied price of $134.45 is 31.9% below the current price of $197.50, suggesting the market is paying a premium despite inferior fundamentals.
Supporting Metrics
